Premium
P1‐238: Randomized, double‐blind, placebo‐controlled study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS 708163) in healthy Japanese and non‐Japanese subjects
Author(s) -
Dockens Randy,
Chung Ellen,
Sverdlov Oleksandr,
Soares Holly,
He Bing,
Furlong Michael,
Tong Gary
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.517
Subject(s) - tolerability , pharmacokinetics , medicine , placebo , cmax , adverse effect , pharmacodynamics , anesthesia , alternative medicine , pathology
of Abs in the inflow blood, the plasma Ab concentrations increased around twice during 1hr extracorporeal treatments. This means the extreme influx of Abs from the outside of blood was triggered by the blood purification, which was similar to the influx observed in hemodialysis patients. Conclusions: The devices with hollow-fiber-fragments were revealed to be excellent Ab adsorbents, as they maintained high Ab removal rates of over 80% for 5hr in vitro. The devices also removed blood Abs effectively in rat extracorporeal systems, which trigged the extreme influx of Abs into the blood. This may suggest the usefulness of Extracorporeal Ab Removal System for AD therapy.